Table 2.
Effects and costs by treatment group and difference at 24-month follow-up
| Pessary therapy n=218 |
Surgery n=221 |
Unadjusted difference (95% CI) |
|
| Effects | |||
| PGI-I, n (%) | 164 (75.1) | 179 (80.8) | −0.06 (−0.15; 0.04) |
| QALY, mean (SE) | 1.80 (0.02) | 1.82 (0.01) | −0.02 (−0.06; 0.02) |
| Costs, mean (SE) | |||
| Intervention costs | 178 (0.2) | 4640 (0) | −4462 (−4463; −4462) |
| Primary care costs | 18 (2) | 15 (2) | 3 (−3; 8) |
| Secondary care costs | 3736 (174) | 1127 (80) | 2609 (2232; 2982) |
| Healthcare costs | 3932 (174) | 5782 (80) | −1850 (−2228; −1476) |
| Absenteeism from paid work | 362 (117) | 390 (120) | −28 (−338; 290) |
| Societal costs | 4294 (227) | 6172 (150) | −1878 (−2395 to to 1345) |
Intervention costs in the pessary group=costs of pessary device and pessary placement consultation at baseline. Intervention costs in the surgery group=DBC costs of surgery at baseline which included one follow-up consultation at 6 weeks. Primary care costs=costs of general practitioner or other healthcare professional consultations apart from the prescheduled follow-up consultations because of complaints related to pelvic organ prolapse symptoms. Secondary care costs=costs of follow-up scheduled consultations with gynaecologists attended by patients and extra consultations due to complications, costs of hospital readmissions due to complications, surgeries after pessary, resurgeries and costs of pessary change.
PGI-I is presented as the difference between groups in the proportion of participants reporting improvement.
%, proportion; DBC, Diagnose Behandeling Combinatie; n, number of participants; PGI-I, Patient Global Impression of Improvement (1=improvement; 0=no improvement); QALY, quality-adjusted life-year; SE, standard error.